Overview of Ursobil

What is Ursobil?

Ursobil is a pharmaceutical formulation containing ursodeoxycholic acid (UDCA), a naturally occurring bile acid found in small quantities in human bile. Unlike primary bile acids, which can be irritating to tissues at high concentrations, ursodeoxycholic acid is a hydrophilic (water-friendly) bile acid known for its cytoprotective properties within the hepatobiliary system.

Composition and Mechanism

The active ingredient in Ursobil works by modifying the composition of the bile acid pool. When taken regularly, it increases the proportion of ursodeoxycholic acid while decreasing the concentration of more toxic, hydrophobic bile acids. This shift helps protect liver cells (hepatocytes) and the lining of the bile ducts from damage.

Ursobil also acts on the cholesterol levels in the bile through two primary methods:

Reduction of Cholesterol Absorption: It limits the amount of cholesterol the intestines absorb from food.
Cholesterol Desaturation: It reduces the amount of cholesterol secreted by the liver into the bile.

Clinical Applications

Ursobil is primarily utilized in the management of conditions where bile flow is impaired or where cholesterol balance in the gallbladder is disrupted. Its applications generally fall into two categories:

Gallstone Dissolution

Ursobil is used to dissolve specific types of gallstones made primarily of cholesterol. By decreasing the cholesterol saturation of bile, the medication allows cholesterol to gradually disperse from the stones back into the bile solution. This process is generally reserved for stones that are radiolucent (transparent to X-rays) and for patients with a functioning gallbladder.

Chronic Liver Diseases

In the context of chronic cholestatic liver diseases, Ursobil is used to promote bile flow and protect liver tissue. By replacing toxic bile acids with the protective ursodeoxycholic acid, it helps reduce inflammation and may slow the progression of scarring in the liver. It is frequently used in conditions such as primary biliary cholangitis (PBC), where the bile ducts are slowly destroyed.

Regulatory References

Ursodiol (Ursodeoxycholic Acid) LiverTox entry

What side effects are possible with Ursobil?

Possible Side Effects and Safety Information

The safety profile of Ursobil (ursodiol) is formally documented in government regulatory texts, outlining adverse reactions primarily by frequency and the affected body system. The most commonly reported events involve the digestive tract.

Frequency-Classified Adverse Reactions

The frequency classification of possible adverse effects, based on regulatory standards, includes:

Very Common (ge 1/10): Diarrhea and pasty stools.
Common (ge 1/100 to < 1/10): Nausea, vomiting, dyspepsia, abdominal pain, and pruritus (itching).

Serious Adverse Reactions and Safety Constraints

Although rare, clinically significant adverse reactions and specific safety constraints are documented. In patients with advanced Primary Biliary Cholangitis (PBC), there is a rare risk of hepatic decompensation, which may necessitate discontinuation of the medicine. The calcification of radiolucent gallstones is another rare documented event, which can render the stones unsuitable for further dissolution therapy.

Safety-Related Restrictions: The official labeling requires regular monitoring of liver function tests (including AST, ALT, and alkaline phosphatase) throughout the course of treatment. The medicine is contraindicated in individuals with acute inflammation of the gallbladder, bile duct occlusion, frequent episodes of biliary colic, or the presence of calcified (radiopaque) gallstones.

Population-Specific Notes: Women of childbearing age are advised to use effective non-hormonal contraception, as hormonal contraceptives may counteract the medicine's effects. Use during pregnancy is generally restricted unless clearly necessary.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents for Ursobil (ursodiol) establish that there have been no reports of accidental or intentional overdosage in humans documented in the official prescribing information. The lack of such reports means that specific, severe clinical manifestations of acute toxicity in humans are not formally detailed in the regulatory profile.

The single clinical manifestation associated with excessive dose intake, described in some regulatory labels, is diarrhoea. This symptom is attributed to the drug’s inherent characteristic of limited systemic absorption at high doses, which results in greater amounts being passed into the faeces. If this symptom occurs, the official guidance is that the dose must be reduced, and therapy should be discontinued if the diarrhoea persists.

Despite the undocumented nature of acute human toxicity, any suspected overdosage is considered an event that requires immediate, professional attention. Emergency medical attention must be sought for any potential overdosage scenario.

Official Overdose Management and Response

Action Type	Regulatory Statement
Required Action	Emergency medical attention must be sought immediately.
Symptom Management	If diarrhoea is present, the dose must be reduced or therapy discontinued entirely if the symptom persists.
General Treatment	Management is described as symptomatic and supportive treatment.
Antidote Status	No specific chemical antidote is mentioned in the official regulatory documentation.

The overdose profile is structured around general emergency protocols and managing the known dose-related gastrointestinal effect, emphasizing the need for professional medical evaluation to ensure appropriate care.

Therapeutic Uses of Ursobil

Quick Facts

Primary Biliary Cholangitis (PBC): Indicated for the management of this chronic liver condition.
Gallstone Dissolution: May be used to facilitate the gradual reduction of small, radiolucent (non-calcified) cholesterol gallstones in selected patients.
Gallstone Prevention: May be used to reduce the risk of gallstone formation in individuals undergoing rapid, significant weight loss.

Ursobil (ursodiol) is a therapeutic agent used in the management of certain conditions related to the liver and gallbladder. Its primary application is in the treatment of Primary Biliary Cholangitis (PBC), a condition that affects the bile ducts in the liver.

The medication is also utilized to address cholesterol gallstones. Specifically, it may be prescribed for patients with small, non-calcified gallstones to promote their slow dissolution as an alternative to surgical intervention, or when surgery presents an increased risk. Ursobil is also indicated as a preventive measure for gallstones in individuals who are experiencing rapid weight loss, such as after certain bariatric procedures.

In these therapeutic areas, the medication is intended to provide a supportive role in overall clinical management, and it may improve liver enzyme levels associated with PBC. Detailed clinical data and specific indications are provided in the professional product information.

Eligibility and Restrictions for Use

Eligibility for Ursobil (Ursodiol) Use

The eligibility for Ursobil is strictly defined by regulatory authorities based on disease status, physical conditions, and patient population.

Absolute Contraindications

Ursobil must not be used by individuals with the following conditions, as they are designated as absolute contraindications in official labeling:

Hypersensitivity or allergy to ursodiol or other bile acids.
Decompensated liver cirrhosis.
Complete obstruction of the bile duct.
Calcified (radio-opaque) gallstones.
Acute inflammation of the gallbladder or biliary tract.
Non-functioning gallbladder (when treating gallstones).

Population Restrictions

Use is not recommended or restricted for certain populations:

Pregnancy and Lactation: Use is generally not recommended during pregnancy or breastfeeding, due to insufficient data or potential risk, and should only be considered if essential.
Pediatric Patients: Use is restricted; it is generally not recommended for children under 6 years of age, though specific indications exist for older children (6-18 years) with cystic fibrosis-related liver disease in some regions.
Intestinal Conditions: Contraindicated in pathological conditions, such as ileal resection, that impair the drug's intended action via enterohepatic circulation.

What should I know about interactions with other medicines?

Ursobil Interactions with Other Medicines and Products

Ursobil (ursodeoxycholic acid) may interact with certain medications and substance classes, primarily by affecting its absorption or counteracting its therapeutic effects.

Interacting Product Category	Examples of Interacting Medicines	Mechanism of Interaction
Bile Acid Sequestering Agents	Cholestyramine, Colestipol, Colesevelam	Adsorb bile acids in the gastrointestinal tract, which can reduce the absorption and effectiveness of Ursobil.
Aluminum-based Antacids	Aluminum Hydroxide, Aluminum Carbonate	Adsorb bile acids, potentially interfering with Ursobil's absorption in a manner similar to sequestering agents.
Lipid-Altering/Hormonal Drugs	Estrogens, Oral Contraceptives, Clofibrate, Gemfibrozil	Increase hepatic cholesterol secretion, which may counteract Ursobil’s action, particularly when it is used for cholesterol gallstone dissolution.
Other Medications	Cyclosporine, Nitrendipine, Dapsone	Ursobil may affect the absorption or metabolism of certain drugs, including those that are substrates of the CYP3A4 enzyme or transport systems.

To minimize potential interactions and ensure optimal effectiveness, bile acid sequestering agents and aluminum-based antacids should generally be administered separately from Ursobil. Drugs that increase cholesterol in the bile may reduce the intended therapeutic benefit of Ursobil; therefore, use of these agents concurrently should be carefully considered.

Mechanism of Action

The mechanism of action of Ursobil (Ursodeoxycholic acid, UDCA) is defined by three complementary pharmacological domains that contribute to the modification of the biliary and liver cellular environment.

Bile Composition Re-engineering

This domain involves UDCA acting as a solubility modulator, primarily by reducing the hepatic synthesis and secretion of cholesterol into the bile. This action lowers the bile's saturation, making it less prone to forming solids, while simultaneously diluting the pool of toxic, hydrophobic bile acids through competitive displacement.

Cellular Protection and Anti-Apoptotic Action

UDCA exerts a cytoprotective and anti-apoptotic effect on liver and bile duct cells. It integrates into and stabilizes cell membranes, rendering them less susceptible to the detergent-like injury caused by toxic bile acids. This mechanism is crucial as it inhibits the formation of the Mitochondrial Permeability Transition (MPT) pore, preventing the intrinsic pathway of cell death.

Choleretic Effect and Transport Modulation

The drug stimulates bile flow through a choleretic mechanism, acting as an upregulator of key canalicular transport proteins like the Bile Salt Export Pump (BSEP). This action enhances the secretion of bile acids and a bicarbonate-rich fluid, which effectively increases bile volume and alkalinity to increase the clearance of accumulating hydrophobic compounds and contribute to a modified biliary environment.

Dosage and Administration Information

Ursobil contains the active ingredient ursodeoxycholic acid (UDCA) and must be taken exactly as prescribed by your doctor. The dosage and treatment duration are highly dependent on the condition being treated, as well as your body weight.

General Administration

Take with food: It is generally recommended to take Ursobil tablets or capsules with a meal or snack. This helps improve the absorption of the medication.
Swallow whole: Tablets and capsules should be swallowed whole with water. If you are prescribed a scored tablet that needs to be broken, swallow the segments immediately and do not chew them, as the drug has a bitter taste.
Consistency: Take your doses at approximately the same time(s) each day to maintain a consistent level of the medication in your body. If you miss a dose, take it as soon as you remember, unless it is close to the time for your next dose; in that case, skip the missed dose. Do not take a double dose.

Dosing Schedules by Indication

The dosage of Ursobil (UDCA) is calculated based on body weight (mg/kg/day) and the specific disorder.

Indication	Typical Daily Dose	Frequency	Duration of Treatment
Dissolution of Cholesterol Gallstones	8 to 10 mg/kg	2 to 3 divided doses, often with the last dose at bedtime.	Up to 2 years, with continued monitoring.
Primary Biliary Cholangitis (PBC)	13 to 15 mg/kg	2 to 4 divided doses with food.	Typically long-term or indefinite.

Monitoring and Treatment Notes

Your doctor will schedule regular check-ups, which include liver function tests (e.g., blood work) every 3 to 6 months to monitor your response to treatment. For gallstone dissolution, ultrasound imaging will be used periodically to check the size and status of the stones. Do not stop treatment without consulting your healthcare provider.

Recent Clinical Evidence

Research evidence / Overview of studies for Ursobil

Evidence for Use in Primary Biliary Cholangitis (PBC)

Research exploring Ursobil for Primary Biliary Cholangitis (PBC) primarily consists of Randomized Controlled Trials (RCTs) and extensive long-term observational studies. These studies examine patient-reported experiences for this chronic liver condition. Researchers monitored changes in liver enzyme levels, tracked as biomarkers of disease activity, and hard clinical endpoints, such as the need for liver transplantation or all-cause mortality.

Findings from short-term trials show that patterns of change were measured in these liver enzyme levels. Long-term observational data and systematic reviews have been applied in studies examining patient-reported experiences and studies describe patterns related to outcomes such as transplantation-free survival in the groups monitored. However, research findings were mixed regarding perceived discomfort and symptoms like fatigue and itching. The long-term effects are not fully established through continuous, controlled research, and the evidence for patients identified as non-responders to the initial therapy is still emerging.

Evidence for Gallstone Dissolution and Prevention

Ursobil was studied for two specific applications: dissolving existing stones and preventing new ones. Controlled clinical trials have been conducted to see if research examined whether it could affect the size or presence of small, non-calcified (radiolucent) cholesterol stones in the gallbladder.

For gallstone dissolution, findings describe patterns observed in the studies where radiological endpoints were achieved in a fraction of the patients. This process was slow, with follow-up durations often extending up to two years. Research measured a difference in the incidence of new gallstones forming in individuals undergoing rapid weight loss compared to a control group, indicating a pattern related to prevention. However, the optimal duration of prophylaxis to cover the entire period of heightened risk is not definitively characterized.

Research Gaps and Areas of Uncertainty

Research provides context but not individual predictions, and evidence highlights what is known and what is still uncertain. A key limitation is that early PBC research often relied on surrogate markers (like liver enzymes) rather than direct clinical endpoints. The study design and results varied across studies due to differences in patient selection and follow-up. For instance, limited information for long-term outcomes exists for special groups like children, and comparative evidence is lacking for certain alternative research comparisons.

Key Studies & References

Dissolution of gallstones by ursodeoxycholic acid (UDCA)

Frequently Asked Questions (FAQ)

Common questions about Ursobil (FAQ)

Q: Does Ursobil work immediately or take time to show effects?

A: Studies and official information indicate that the medicine works over time, not immediately. For dissolving gallstones, effects are monitored in clinical trials over several months, with treatment often extending up to two years. For liver conditions, changes in liver markers are often tracked after the first few months of treatment.

Q: Is it common to feel mild nausea when starting Ursobil?

A: According to the official product information, nausea is reported as a common adverse reaction in clinical studies. This is one of the frequently observed effects reported in clinical experience.

Q: Is it normal to have mild diarrhea after starting Ursobil treatment?

A: Regulatory documents classify diarrhea and pasty stools as very common adverse reactions. These are among the most frequently reported side effects observed during the use of this medicine.

Q: How long is a typical course of treatment with Ursobil for gallstones?

A: For the purpose of dissolving gallstones, the duration required is usually several months. Treatment often continues for an extended period, which may be up to two years.

Q: What should a patient do if they accidentally miss a dose of Ursobil?

A: Official information advises that if a dose is missed, it should be taken as soon as it is remembered. However, if it is close to the time for the next scheduled dose, regulatory guidance indicates that the missed dose is to be skipped.

Q: Does the time of day a person takes Ursobil matter?

A: For certain indications like gallstone treatment, the official dosing information indicates that the total daily dose is often divided. Official information indicates that, for gallstone treatment, a dose is often recommended to be taken at bedtime.

Q: Does Ursobil interact with birth control pills?

A: Official drug labeling indicates that hormonal contraceptives, particularly those containing estrogen, may counteract the therapeutic effect of Ursobil. This information is noted on the official labeling.

Q: What is the connection between Ursobil and liver health?

A: Ursobil is formally described as a hepatoprotective agent and is indicated for the treatment of Primary Biliary Cholangitis (PBC), a chronic liver disease. Its function involves protecting liver cells and modifying the composition of bile.

Q: Can Ursobil affect the results of liver function tests?

A: Official labeling states that liver function tests (blood work to check the liver) must be monitored regularly during treatment. If these results increase significantly, regulatory documents state that discontinuation may be indicated.

Q: What is the difference between primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) in relation to Ursobil?

A: Primary Biliary Cholangitis (PBC) is a specific approved indication for Ursobil treatment. Regulatory guidance does not include Primary Sclerosing Cholangitis (PSC) as a specific approved indication for this medicine.

Q: Is Ursobil the same as natural bile salts?

A: The active ingredient, ursodeoxycholic acid, is a compound that is naturally found in human bile. However, the pharmaceutical-grade drug used in Ursobil is chemically synthesized to guarantee the high purity and consistency required for clinical treatment.

Q: Can Ursobil be taken by someone who has had a previous allergic reaction to medicine?

A: Official product information specifies that Ursobil is contraindicated (use is not permitted) in individuals who have a known hypersensitivity or allergy to ursodiol or any other type of bile acid.

Q: Can Ursobil be used for conditions other than gallstones or liver disease?

A: Regulatory documents list specific approved indications, which are the dissolution of cholesterol gallstones and the treatment of Primary Biliary Cholangitis. The regulatory documentation does not address use outside of these specific, approved indications.

Q: Can men and women use Ursobil equally, or are there gender-specific warnings?

A: Official drug labeling is similar for men and women. However, official information specifies that women of childbearing age should use effective non-hormonal contraception while undergoing treatment.

Q: Is Ursobil known to cause any long-term effects on the digestive system?

A: The most common and very common side effects reported during long-term clinical experience are related to the digestive system, including diarrhea and pasty stools.

Q: What are the general success rate mentioned in studies for dissolving gallstones with Ursobil?

A: Official drug information reports that complete dissolution of gallstones does not occur in all patients treated with Ursobil. Complete dissolution has been observed in a fraction of individuals monitored in clinical trials.

Q: Are there special warnings about using Ursobil in patients with kidney issues?

A: Regulatory documents state that no specific dose adjustment is typically required for patients who have kidney impairment. However, as with all medications, caution may be advised in certain situations.

Q: Does Ursobil carry a risk of liver damage?

A: Ursobil is described as protective of the liver, but official warnings state that there is a rare documented risk of hepatic decompensation (worsening liver function) in patients with advanced liver disease. Regular monitoring of liver function tests is required to detect any potential issues.

Q: What happens if Ursobil treatment is stopped suddenly?

A: Official information advises against discontinuing treatment without first consulting a healthcare provider. Studies have also reported that gallstone recurrence is common following successful dissolution.

Q: Are children or teenagers ever prescribed Ursobil?

A: The use of the medicine is restricted for pediatric populations. However, regulatory documents state that it is indicated for specific liver disorders associated with cystic fibrosis in children aged 6 to 18 years in some regions.

Q: Why might a doctor prescribe Ursobil to a patient who still has their gallbladder?

A: The medicine is approved for the dissolution of gallstones in patients who have a functioning gallbladder. This is the official indication for the drug.

Q: Is it common for studies to report recurrence of gallstones after stopping Ursobil?

A: Official drug information and clinical studies have reported that the recurrence of gallstones is common and may occur within five years after the successful dissolution of the original stones.

Q: Are there restrictions on driving or operating machinery while taking Ursobil?

A: Regulatory documents state that Ursobil is generally considered to have no influence on a person's ability to drive or use machines.

Q: Is Ursobil intended to prevent gallstones from forming?

A: The medicine is officially indicated for the prevention of gallstone formation in individuals who are classified as obese patients undergoing rapid or significant weight loss.

How should Ursobil be stored and disposed of?

The drug Ursobil (ursodiol) must be stored and handled according to specific official requirements to maintain its stability and effectiveness.

Labeled Storage Conditions

Requirement	Official Statement
Temperature	Store at 20°C to 25°C (68°F to 77°F), which is defined as controlled room temperature. Brief excursions between 15°C and 30°C (59°F and 86°F) are typically permitted.
Protection	Keep the medication in the container it was provided in, tightly closed, and dispense in a tight, light-resistant container as defined by the USP. Protect from excess heat and moisture.
Stability (Split Tablet)	If a scored tablet is broken, the segments should be stored separately from whole tablets due to bitter taste. Use split segments within 28 days of breaking.

Disposal and Safety

Child Protection: Keep this medication out of sight and out of reach of children.
Disposal: Do not dispose of unused or expired medicine via household waste or wastewater (e.g., flushing down the toilet or sink) unless specifically instructed by a healthcare professional. Dispose of the medication according to local regulations or a drug take-back program to ensure safe environmental handling.

Ursobil